CRA experts advised two parties during both the CMA’s investigation and CAT Appeals, assessing the economic evidence and providing expert testimony on what prices could be considered excessive (or, to the contrary, consistent with competitive outcomes) in the UK market for Liothyronine tablets.
CRA's Competition & Antitrust Practice commemorates Canada Day
Our Toronto team advises clients on complex antitrust, merger, and regulatory matters in Canada, Europe, and the United States. We would like to take this...